ArticleAdvances in urology2012
Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer.
Article in Advances in urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Assessment of DNA damage and telomerase activity in exfoliated urinary cells as sensitive and noninvasive biomarkers for early diagnosis of bladder cancer in ex-workers of a rubber tyres industry.BioMed research international · 2014Trial
- Urine-Based Approaches for Screening, Diagnosis, and Surveillance of Urothelial Carcinoma.Journal of personalized medicine · 2026Review
- Review
- Urinary DNA-methylation and protein biomarkers identify urothelial carcinoma among other genitourinary diseases and cancer-free individuals.Journal of translational medicine · 2024Article
- Epigenetic approaches for cervical neoplasia screening (Review).Experimental and therapeutic medicine · 2021Review
- Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.Molecular biology reports · 2021Article
- Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet.Frontiers in genetics · 2019Review
- Regulation of sex hormone receptors in sexual dimorphism of human cancers.Cancer letters · 2018Review
- Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma.Oncotarget · 2017Article
- Biomarkers for precision medicine in bladder cancer.International journal of clinical oncology · 2017Review
- Genetic and Epigenetic Alterations in Bladder Cancer.International neurourology journal · 2016Review
- Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?World journal of biological chemistry · 2015Review
- Epigenetic silencing of the MUPCDH gene as a possible prognostic biomarker for cyst growth in ADPKD.Scientific reports · 2015Article
- [Epigenetics in urothelial cancer: Pathogenesis, improving diagnostics and developing novel treatment options].Der Urologe. Ausg. A · 2015Article
- Gene microarray analysis of the lncRNA expression profile in human urothelial carcinoma of the bladder.International journal of clinical and experimental medicine · 2014Article
- Molecular signatures in urologic tumors.International journal of molecular sciences · 2013Review
- Urinary tumor markers could predict survival in bladder carcinoma.Indian journal of clinical biochemistry : IJCB · 2013Article
- Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests.Molecular diagnosis & therapy · 2013Review
- Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer of the urinary bladder is the fifth most common neoplasm in the industrialized countries. Diagnosis and surveillance are dependent on invasive evaluation with cystoscopy and to some degree cytology as an adjunct analysis. Nomuscle invasive bladder cancer is characterized by frequent recurrences after resection, and up to 30% will develop an aggressive phenotype. The journey towards a noninvasive test for diagnosing bladder cancer, in order to replace or extend time between cystoscopy, has been ongoing for more than a decade. However, only a handful of tests that aid in clinical decision making are commercially available. Recent reports of DNA methylation in urine specimens highlight a possible clinical use of this marker type, as high sensitivities and specificities have been shown. This paper will focus on the currently available markers NMP22, ImmunoCyt, and UroVysion as well as novel DNA methylation markers for diagnosis and surveillance of bladder cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.